| Literature DB >> 34178025 |
Yixin Gao1, Jinhui Zhang1, Huashuo Zhao1,2, Fengjun Guan3, Ping Zeng1,2.
Abstract
BACKGROUND: In two-sample Mendelian randomization (MR) studies, sex instrumental heterogeneity is an important problem needed to address carefully, which however is often overlooked and may lead to misleading causal inference.Entities:
Keywords: anthropometric traits; breast cancer; causal effect estimation; prostate cancer; sex heterogeneity; sex-specific and sex-combined instrumental variable; summary statistics; two-sample Mendelian randomization
Year: 2021 PMID: 34178025 PMCID: PMC8220153 DOI: 10.3389/fgene.2021.651332
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Genetic variants with significant sex difference in effect size for four anthropometric traits.
| Traits | Gene | CHR | POS | SNP | Effect | Folds | References | ||
| Female | Male | ||||||||
| BMI | 20 | 51,087,862 | rs6091540 | 0.030 (0.004) | 0.007 (0.005) | 9.05E-05 | 4.3 | ||
| BMI | 1 | 177,889,480 | rs543874 | 0.060 (0.005) | 0.034 (0.005) | 5.23E-05 | 1.8 | ||
| WHR | 1 | 217,820,132 | rs2820443 | 0.062 (0.005) | 0.002 (0.005) | 2.60E-17 | 31.0 | ||
| WHR | 1 | 217,817,340 | rs4846567 | 0.059 (0.005) | 0.005 (0.005) | 1.18E-13 | 11.8 | ||
| WHR | 2 | 165,221,337 | rs10195252 | 0.054 (0.005) | 0.010 (0.005) | 1.41E-11 | 5.4 | ||
| WHR | 6 | 43,872,529 | rs1358980 | 0.060 (0.005) | 0.015 (0.005) | 3.70E-11 | 4.0 | ||
| WC | 1 | 245,717,763 | rs10925060 | 0.002 (0.005) | 0.045 (0.006) | 1.70E-08 | 22.5 | ||
| WC | 5 | 159,626,935 | rs17472426 | −0.014 (0.009) | 0.052 (0.010) | 3.90E-08 | 3.7 | ||
| HIP | 6 | 53,648,294 | rs7739232 | 0.063 (0.011) | −0.004 (0.014) | 2.90E-05 | 15.8 | ||
| HIP | 9 | 122,533,883 | rs7044106 | 0.039 (0.007) | −0.003 (0.008) | 1.30E-05 | 13.0 | ||
| HIP | 7 | 130,090,402 | rs13241538 | 0.033 (0.005) | −0.003 (0.005) | 2.00E-09 | 11.0 | ||
Summary information of the GWAS datasets employed in our sex-specific two-sample MR analysis.
| Trait | Sample size (case/control) | References | ||
| Sex-combined | 322,154 | 97 | 2,517,828 | |
| Female-specific | 171,977 | 38 | 2,459,695 | |
| Male-specific | 152,893 | 30 | 2,443,565 | |
| Sex-combined | 210,086 | 39 | 2,542,431 | |
| Female-specific | 116,742 | 34 | 2,467,778 | |
| Male-specific | 93,480 | 3 | 2,146,136 | |
| Sex-combined | 231,355 | 70 | 2,545,772 | |
| Female-specific | 127,470 | 25 | 2,473,035 | |
| Male-specific | 104,079 | 29 | 2,294,965 | |
| Sex-combined | 211,117 | 89 | 2,540,653 | |
| Female-specific | 117,340 | 41 | 2,466,814 | |
| Male-specific | 93,965 | 31 | 2,188,855 | |
| 228,951 (122,977/105,974) | ||||
| Female-specific | 13,011,123 | |||
| 140,306 (79,194/61,112) | ||||
| Male-specific | 16,486,833 | |||
FIGURE 1Genetic correlation between sex-combined and sex-specific anthropometric traits as well as between male-specific and female-specific anthropometric traits using (A) linkage disequilibrium score regression (LDSC) and (B) Pearson’s correlation analyses. BMI, body mass index; WHR, waist-to-hip ratio; WC, waist circumference; HIP, hip circumference.
FIGURE 2Estimated causal effects with sex-combined or sex-specific instrumental variables in the simulation. (A,D) The true causal effect is 0.1. (B,E) The true causal effect is 0.3. (C,F) The true causal effect is 0.5. In the top panel, the phenotypic variance explained (PVEs) of the male and the female exposures are 1 and 3%, respectively. In the bottom panel, the PVEs of the male and the female exposures are 3 and 1%, respectively.
Association of anthropometric trait with the risk of breast cancer using sex-combined and female-specific instruments.
| Exposure | Sex-combined IVs | Female-specific IVs | |||||||
| PVE (%) | Power (%) | OR (95% CI, | PVE (%) | Power (%) | OR (95% CI, | ||||
| BMI | 97/92 | 1.51 | 99.9 | 0.845 (0.756∼0.945, 0.003) | 38/36 | 1.16 | 100.0 | 0.763 (0.661∼0.882, 2.52E-04) | 4.795 (1.63E-06) |
| WHR | 39/38 | 0.95 | 2.8 | 1.002 (0.841∼1.194, 0.984) | 34/34 | 1.63 | 6.7 | 0.985 (0.858∼1.131, 0.833) | 0.610 (0.542) |
| WC | 70/66 | 1.42 | 98.0 | 0.866 (0.767∼0.978, 0.020) | 25/25 | 1.04 | 96.1 | 0.858 (0.732∼1.004, 0.057) | 0.299 (0.765) |
| HIP | 89/86 | 2.07 | 6.1 | 0.988 (0.885∼1.102, 0.823) | 41/39 | 1.57 | 93.6 | 0.890 (0.787∼1.006, 0.063) | 9.669 (1.25E-20) |
Association of anthropometric trait with the risk of prostate cancer using sex-combined and male-specific instruments.
| Exposure | Sex-combined IVs | Male-specific IVs | |||||||
| PVE (%) | Power (%) | OR (95% CI, | PVE (%) | Power (%) | OR (95% CI, | ||||
| BMI | 97/60 | 1.12 | 81.3 | 0.865 (0.764∼0.979, 0.022) | 30/22 | 0.77 | 67.7 | 0.862 (0.738∼1.007, 0.060) | 0.190 (0.849) |
| WHR | 39/21 | 0.56 | 59.2 | 0.854 (0.681∼1.071, 0.172) | 3/1 | 0.04 | 5.2 | 1.094 (0.545∼2.198, 0.800) | −0.969 (0.333) |
| WC | 70/50 | 1.02 | 14.1 | 0.954 (0.808∼1.126, 0.577) | 29/21 | 1.15 | 59.0 | 0.895 (0.763∼1.050, 0.175) | 2.688 (0.007) |
| HIP | 89/64 | 1.40 | 5.4 | 1.016 (0.886∼1.166, 0.817) | 31/17 | 0.83 | 28.6 | 1.086 (0.873∼1.350, 0.457) | −1.428 (0.153) |
FIGURE 3Estimated causal effects of BMI on breast cancer with different MR approaches. MR-Egger regression was performed after removing the instrument of rs17024393. BMI, body mass index; IV, instrumental variable; IVW, inverse-variance weighted; OR, odds ratio; MR, Mendelian randomization.